DRPevader: Ex vivo-diagnosis and prognosis of early diabetic retinopathy
A novel ex vivo method for immediate early diagnosis and prognosis of proliferative diabetic retinopathy (DRP) is provided with DRPevader.
DRPevader is based on the analysis of expression and activity of very few genes which can simply be determined using whole blood or a blood component. Therefore, DRPevader is the diagnostic link between the alteration of leukocyte gene expression, the activity of specific serum-markers, and proliferative DRP.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work
Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…
New SPECT/CT technique shows impressive biomarker identification
…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…
How 3D printers can give robots a soft touch
Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…
